Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
PHP Toggle Menu

Category: TG4010

Transgene Announces Publication in “The Lancet Oncology” of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer

20151223_TIME Ph2b Lancet Oncology 2015_PR EN

Published 23 December 2015
Categorized as 2015, Press release, TG4010

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

Elisabeth Quoix, et al. The Lancet Oncology, December 2015, 17: 212–23 – Download the article Publication

Published 18 December 2015
Categorized as -others, 2015, Publication, TG4010

TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced NSCLC: Phase 2b Results of the TIME trial

John Nemunaitis, et al. SITC 2015, November 2015 – Abstract available on the SITC website Download the poster here Poster Presentation

Published 13 November 2015
Categorized as -others, 2015, Publication, TG4010

TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results.

Elisabeth Quoix, et al. 16th World Conference on Lung Cancer. September 2015, Denver, Colorado Download the poster here Poster Presentation

Published 10 September 2015
Categorized as -others, 2015, Publication, TG4010

Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer

20150908 PR TG4010 IASLC revised – BIS

Published 8 September 2015
Categorized as 2015, Press release, TG4010

Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer

19 August 2015_PR_IASLC curtain raiser_ENG

Published 19 August 2015
Categorized as 2015, Press release, TG4010

Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (poster)

20150601 PR TG4010 TIME results_ASCO 2015_FINAL

Published 1 June 2015
Categorized as 2015, Press release, TG4010

Results of the Phase 2B Part of Time Study Evaluating TG4010 Immunotherapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy

Elisabeth Quoix, et al. ASCO Annual Meeting 2015 – May 29-June 2, 2015 – Chicago, Illinois Download the poster here Poster Presentation

Published 1 June 2015
Categorized as -others, 2015, Publication, TG4010

Transgene Presents New Pre-Clinical Data at AACR on (i) the Combination of TG4010 with Immune Checkpoint Inhibitors; (ii) TG3003, an Anti-CD115 Monoclonal Antibody

20150421 AACR 2015_English

Published 21 April 2015
Categorized as 2015, Press release, TG3003, TG4010

Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer

Poster TG4010-AACR 2015-KR Karola Rittner, et al. AACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2497 Download the posterhere Poster Presentation

Published 21 April 2015
Categorized as -others, 2015, Publication, TG4010

Posts pagination

Newer posts Page 1 Page 2 Page 3 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
Menu